Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Phase 2
Completed
NCT05065970
| Condition | Immunoglobulin A Nephropathy |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | HI-Bio, A Biogen Company |
|---|
| Status | Completed |
|---|
| Enrollment | 54 participants |
|---|
| Interventions | Felzartamab |
|---|
| Start date | Aug 31, 2021 |
|---|
| Completion date | Feb 6, 2023 |
|---|
| Results posted | Apr 28, 2026 |
|---|
Summary
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9
Baseline, Month 9 · gram per gram (g/g)
| Part 1: Placebo | -24.7 ± 19.43 gram per gram (g/g) |
|---|
| Part 1: Felzartamab Dosing Arm M1 | -16.5 ± 19.41 gram per gram (g/g) |
|---|
| Part 1: Felzartamab Dosing Arm M2 | -30.6 ± 21.72 gram per gram (g/g) |
|---|
| Part 1: Felzartamab Dosing Arm M3 | -38.5 ± 16.60 gram per gram (g/g) |
|---|
| p-value | 0.6837 |
|---|
| Geometric LS Mean Ratio | 1.11 (95% CI 0.67–1.84) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.